Brought to you by 
Eisai, Teva co-develop and co-market rasagiline
27 Jul 2006
Executive Summary
Eisai will co-develop worldwide Teva Pharmaceutical Industries' (CNS therapeutics) rasagiline (TVP-1012), a drug candidate that is in Phase II studies for Alzheimer's disease and has recently completed Phase III trials for Parkinson's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai, Teva co-develop and co-market rasagiline
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice